新股配售 | 泰格醫藥:1手中簽率5%,公開認購414.39倍,國配認購20倍,頂頭槌114張
uSMART友信智投8月6日消息,泰格醫藥今日公佈分配結果。
1、定價
100港元,為招股價區間88-100港元的上限,較A股5日收市價111.7元折價約19.4%。
2、中簽率
1手中簽率5%,申購60手穩中1手。甲尾可中6手,乙頭中7手,頂頭槌中86手。
3、公開發售
認購人數為31.9984萬,認購倍數約414.39倍。
其中甲組認購人數31.0395萬,認購倍數247.27倍,乙組認購人數9589,認購倍數581.51倍。頂頭槌申購張數有114。
由於認購倍數超過96倍,啟動回撥機制後公開發售的股份數目佔比提高到21.5%。
4、國際配售
認購倍數約20倍,屬於非常火熱的程度,與金融街物業、華夏視聽教育等熱門股相當,超過思摩爾國際、祖龍娛樂等,承配人總數為328。
5、超額配股權
國配中已超額分配1605.97萬股,佔初始發售股份的15%。穩定價格操作人為美銀美林,穩價期將於8月30日結束。
6、關聯客戶承配人


中簽分配表如下:


股權集中度:

免責聲明:本文所載的所有資料、資料等(「資料」)只供參考之用,不構銷售或建議任何投資、交易策略或金融產品的要約或招攬。本公司會盡力確保資料的準確性及可靠性, 但不保證該資料為準確無誤, 亦不承擔因任何不準確或遺漏而引起的損失或損害。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.